Literature DB >> 8637236

Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines.

U Dehmel1, H Quentmeier, H G Drexler.   

Abstract

We have previously shown that the growth factor FLT3 ligand (FL) is mitogenic for human primary and continuously cultured myeloid leukemia cells. Despite widespread expression of the receptor FLT3 among the leukemia cell lines from certain cell lineages, only two growth factor-dependent myeloid leukemia cell lines showed a significant proliferative response to FL. In the present study, we examined the proliferative effects of FL on a comprehensive set of growth factor-dependent leukemia cell lines. A significant enhancement of cell growth by FL was seen in 10/12 myelomonocytic cell lines, while all cell lines with predominantly megakaryocytic and/or erythroid characteristics did not respond positively, despite the expression of the receptor. The cytokines interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and stem cell factor (SCF) could independently enhance the FL-stimulated proliferation in a synergistic fashion. Transforming growth factor-(beta)1 (TGF-(beta)1), in a dose-dependent fashion, partially inhibited the FL-promoted proliferation, but basic fibroblast growth factor (bFGF), on its own augmenting the response to FL, significantly abrogated the inhibitory effects of TGF-(beta)1. TGF-(beta)1 down-regulated mRNA and protein expression of the FLT3 receptor. Taken together these data suggest that the effects of FL on the growth of normal and malignant hematopoietic cells can be positively and negatively modulated by other cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637236

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 3.  FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.

Authors:  Hitoshi Kiyoi
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

4.  Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia.

Authors:  Larisa Broglie; Jill Gershan; Michael J Burke
Journal:  Int J Hematol Oncol       Date:  2019-01-16

5.  Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.

Authors:  Ami B Patel; Anthony D Pomicter; Dongqing Yan; Anna M Eiring; Orlando Antelope; Jonathan A Schumacher; Todd W Kelley; Srinivas K Tantravahi; Tibor J Kovacsovics; Paul J Shami; Thomas O'Hare; Michael W Deininger
Journal:  Leukemia       Date:  2020-05-14       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.